EP949 Cytoreduction plus HIPEC in advanced ovarian cancer: 10-year experience of the naval and veterans hospital of athens

Introduction/Background Ovarian cancer is the most common cause of gynecological malignancy mortality in the western world. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a method of locoregional treatment that has recently been applied to selected patients. The present study presents the 10-year experience of our department in the use of cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer. Methodology From 2009 to 2018, 30 patients with an average age of 56.6 years (37–78 years) underwent cytoreductive surgery plus HIPEC for ovarian cancer. In 9 cases, interval cytoreductive surgery was performed, and in 21 cases it was performed for tumor recurrence. Outcomes were evaluated by recording the complications and mortality of the method, as well as disease-free survival and overall survival of patients. Results The mean intraoperative PCI score was 19 (2–39). The mean operation time was 318 minutes (180–490). Optimal cytoreduction (CC-0/1) was achieved in 29 cases. In 1 case CC-2 was conducted. The mean postoperative ICU stay was 1.6 days, and the mean postoperative hospital stay was 21.6 days (9–45). Severe (Grade III/IV) complications were documented in 8 cases (26.7%).There was one case of postoperative mortality (3,3%). The mean follow-up period was 28.4 months. The median disease - free survival was 24 months for the interval CRS group, and 17 months for the recurrence group, whereas the median overall survival was 42 months for both groups. Conclusion The implementation of CRS and HIPEC for peritoneal carcinomatosis is a safe option, in a certified center for the treatment of peritoneal surface malignancy. Our results indicate a benefit in terms of disease - free and overall survival in patients undergoing CRS and HIPEC, however the small sample and low number of events inhibit an analysis that would provide safe conclusions at present. Disclosure Nothing to disclose.